IL190619A0 - Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases - Google Patents
Use of soluble guanylate cyclase activators for treating acute and chronic lung diseasesInfo
- Publication number
- IL190619A0 IL190619A0 IL190619A IL19061908A IL190619A0 IL 190619 A0 IL190619 A0 IL 190619A0 IL 190619 A IL190619 A IL 190619A IL 19061908 A IL19061908 A IL 19061908A IL 190619 A0 IL190619 A0 IL 190619A0
- Authority
- IL
- Israel
- Prior art keywords
- lung diseases
- guanylate cyclase
- treating acute
- chronic lung
- soluble guanylate
- Prior art date
Links
- 208000019693 Lung disease Diseases 0.000 title 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 239000003119 guanylate cyclase activator Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005047946A DE102005047946A1 (en) | 2005-10-06 | 2005-10-06 | Use of soluble guanylate cyclase activators for the treatment of acute and chronic lung diseases |
| PCT/EP2006/009264 WO2007039155A2 (en) | 2005-10-06 | 2006-09-23 | Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL190619A0 true IL190619A0 (en) | 2008-12-29 |
Family
ID=37106347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL190619A IL190619A0 (en) | 2005-10-06 | 2008-04-03 | Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090286781A1 (en) |
| EP (1) | EP1945218A2 (en) |
| JP (1) | JP2009510142A (en) |
| KR (1) | KR20080065283A (en) |
| CN (1) | CN101282727A (en) |
| AU (1) | AU2006299149A1 (en) |
| BR (1) | BRPI0616921A2 (en) |
| CA (1) | CA2624716A1 (en) |
| DE (1) | DE102005047946A1 (en) |
| IL (1) | IL190619A0 (en) |
| RU (1) | RU2417083C2 (en) |
| WO (1) | WO2007039155A2 (en) |
| ZA (1) | ZA200802874B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202008014557U1 (en) | 2008-10-27 | 2009-03-12 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Therapeutic use |
| EP2531187B1 (en) * | 2010-02-05 | 2015-08-12 | Adverio Pharma GmbH | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| EP2585055A1 (en) * | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| CN102485724B (en) * | 2010-12-06 | 2015-08-12 | 中国人民解放军军事医学科学院毒物药物研究所 | Substituted thiophene base pyrazolo-pyridines and medicinal use thereof |
| US9090610B2 (en) * | 2011-04-21 | 2015-07-28 | Bayer Intellectual Property Gmbh | Fluoroalkyl-substituted pyrazolopyridines and use thereof |
| LT2875003T (en) * | 2012-07-20 | 2017-02-27 | Bayer Pharma Aktiengesellschaft | New 5-aminotetrahydroquinoline-2-carboxylic acids und their use |
| EP3024455A1 (en) | 2013-07-25 | 2016-06-01 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
| CN108785309A (en) * | 2018-04-23 | 2018-11-13 | 周静 | Purposes of the compound in the drug for preparing treatment chronic lung disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889056A (en) * | 1994-06-15 | 1999-03-30 | Glaxo Wellsome Inc. | Enzyme inhibitors |
| DE19834044A1 (en) * | 1998-07-29 | 2000-02-03 | Bayer Ag | New substituted pyrazole derivatives |
| DE19943635A1 (en) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Novel aminodicarboxylic acid derivatives with pharmaceutical properties |
| AR031176A1 (en) * | 2000-11-22 | 2003-09-10 | Bayer Ag | NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE |
| EP1501605A1 (en) * | 2002-04-26 | 2005-02-02 | ALTANA Pharma AG | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency |
| DE10220570A1 (en) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamate-substituted pyrazolopyridines |
| GB2395431A (en) * | 2002-11-20 | 2004-05-26 | Northwick Park Inst For Medica | Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide |
| WO2005013691A1 (en) * | 2003-08-04 | 2005-02-17 | Hemocorm Limited | Use of boranocarbonates for the therapeutic delivery of carbon monoxide |
| JP2007505142A (en) * | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | Potassium channel-mediated delivery of drugs across the blood brain barrier |
| GB0325291D0 (en) * | 2003-10-29 | 2003-12-03 | Pfizer Ltd | Novel combination |
| DE10351903A1 (en) * | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | New combination |
| WO2005077005A2 (en) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Enhancing the effectiveness of an inhaled therapeutic gas |
| CA2583073A1 (en) * | 2004-10-05 | 2006-04-13 | Bayer Healthcare Ag | A guanylane cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasoconstriction |
-
2005
- 2005-10-06 DE DE102005047946A patent/DE102005047946A1/en not_active Withdrawn
-
2006
- 2006-09-23 CA CA002624716A patent/CA2624716A1/en not_active Abandoned
- 2006-09-23 AU AU2006299149A patent/AU2006299149A1/en not_active Abandoned
- 2006-09-23 US US12/083,121 patent/US20090286781A1/en not_active Abandoned
- 2006-09-23 KR KR1020087010682A patent/KR20080065283A/en not_active Ceased
- 2006-09-23 EP EP06777198A patent/EP1945218A2/en not_active Withdrawn
- 2006-09-23 WO PCT/EP2006/009264 patent/WO2007039155A2/en not_active Ceased
- 2006-09-23 RU RU2008117303/15A patent/RU2417083C2/en not_active IP Right Cessation
- 2006-09-23 JP JP2008533900A patent/JP2009510142A/en active Pending
- 2006-09-23 BR BRPI0616921-0A patent/BRPI0616921A2/en not_active IP Right Cessation
- 2006-09-23 CN CNA2006800373890A patent/CN101282727A/en active Pending
-
2008
- 2008-04-02 ZA ZA200802874A patent/ZA200802874B/en unknown
- 2008-04-03 IL IL190619A patent/IL190619A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE102005047946A1 (en) | 2007-05-03 |
| CA2624716A1 (en) | 2007-04-12 |
| BRPI0616921A2 (en) | 2011-07-05 |
| RU2417083C2 (en) | 2011-04-27 |
| KR20080065283A (en) | 2008-07-11 |
| WO2007039155A3 (en) | 2007-10-11 |
| JP2009510142A (en) | 2009-03-12 |
| CN101282727A (en) | 2008-10-08 |
| US20090286781A1 (en) | 2009-11-19 |
| AU2006299149A1 (en) | 2007-04-12 |
| RU2008117303A (en) | 2009-11-20 |
| EP1945218A2 (en) | 2008-07-23 |
| WO2007039155A2 (en) | 2007-04-12 |
| ZA200802874B (en) | 2009-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL190619A0 (en) | Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases | |
| IL188657A0 (en) | Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders | |
| GB2434604B (en) | Porous composites containing hydrocarbon-soluble well treatment agents and methods for using the same | |
| EP2007385A4 (en) | Cardiovascular composition and use the same for the treatment of alzheimers disease | |
| IL182010A0 (en) | Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases | |
| IL189602A0 (en) | Indenoisoquinolinone analogs and methods of use thereof | |
| IL191810A (en) | Dll4 antagonists and vegf inhibitor for use in methods for inhibiting tumor development or growth | |
| ZA200801822B (en) | Pyrazine derivatives and use as p13k inhibitors | |
| IL176958A0 (en) | Compounds and methods of use | |
| IL198397A0 (en) | Anilinopiperazine derivatives and methods of use thereof | |
| EP2054063A4 (en) | 4-aminoquinazoline derivatives and methods of use thereof | |
| IL225911A (en) | Citrulline-containing compositions for use in treating asthma | |
| IL193693A0 (en) | Purine compounds and methods of use thereof | |
| PL2057153T3 (en) | (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline | |
| IL196763A0 (en) | Non-flushing niacin analogues, and methods of use thereof | |
| PT2101731T (en) | Endoxifen for use in the treatment of cancer | |
| IL185309A0 (en) | Isoqunoline compounds and methods of use thereof | |
| IL192031A0 (en) | Use of cicletanine and other furopyridines for treatment of hypertension | |
| PL1774356T3 (en) | Process for the determination of lipoproteins in body fluids | |
| PL2410047T3 (en) | Oxidoreductase and its use for the reduction of secodione derivatives | |
| ZA200609141B (en) | Compositions for Inhalation therapy and methods of use | |
| PL1867241T3 (en) | Seasoning having function of imparting body | |
| EP1812451A4 (en) | Compounds and methods of use thereof | |
| ZA200800025B (en) | Use of soluble guanylate cyclase activators for treating reperfusion damage | |
| ZA200800243B (en) | Use of thiazole derivatives and analogues in the treatment of cancer |